Author: Norio Yamamoto; Shutoku Matsuyama; Tyuji Hoshino; Naoki Yamamoto
Title: Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. Document date: 2020_4_8
ID: 662pfa61_12
Snippet: Nelfinavir showed the lowest EC 50 (1.13 µM), the highest SI (23.32), the second highest C max -EC 50 ratio (6.23), and the highest C trough -EC 50 ratio (3.43) among the tested HIV-1 protease inhibitors. These data indicate that nelfinavir is the best of nine drugs as a potential drug candidate for the treatment of COVID-19. Lopinavir showed the inferior results to nelfinavir, namely, higher EC 50 (5.73 µM), lower SI (12.99), lower C max -EC 5.....
Document: Nelfinavir showed the lowest EC 50 (1.13 µM), the highest SI (23.32), the second highest C max -EC 50 ratio (6.23), and the highest C trough -EC 50 ratio (3.43) among the tested HIV-1 protease inhibitors. These data indicate that nelfinavir is the best of nine drugs as a potential drug candidate for the treatment of COVID-19. Lopinavir showed the inferior results to nelfinavir, namely, higher EC 50 (5.73 µM), lower SI (12.99), lower C max -EC 50 ratio (2.72), and lower C trough -EC 50 ratio (1.97) than nelfinavir. In a recent randomized, controlled, open-label trial, lopinavir-ritonavir did not significantly accelerate clinical improvement, reduce 28-day mortality, or decrease throat viral RNA amount in patients with severe COVID-19 6 . One of the reasons why the efficacy of author/funder. All rights reserved. No reuse allowed without permission.
Search related documents:
Co phrase search for related documents- clinical improvement accelerate and open label trial: 1
- clinical improvement and control open label trial: 1, 2, 3, 4, 5, 6
- clinical improvement and drug candidate: 1
- clinical improvement and mortality reduce: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- clinical improvement and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical improvement and open label trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66
- clinical improvement and protease inhibitor: 1, 2, 3, 4, 5, 6
- clinical improvement and randomized control open label trial: 1, 2, 3
- clinical improvement and treatment drug candidate: 1
- control open label trial and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- control open label trial and open label trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- control open label trial and protease inhibitor: 1
- control open label trial and randomized control open label trial: 1, 2, 3, 4, 5, 6, 7, 8, 9
- drug candidate and mortality reduce: 1, 2, 3, 4, 5, 6, 7
- drug candidate and open label: 1, 2, 3, 4
- drug candidate and open label trial: 1
- drug candidate and potential treatment drug candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- drug candidate and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- drug candidate and treatment drug candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
Co phrase search for related documents, hyperlinks ordered by date